This retrospective study explored associations between inflammation-related peripheral blood markers (NLR, LDH, and PNI), and outcome and onset of irAEs in patients with advanced NSCLC receiving PD-1 inhibitors. Here, PDCD1 is linked to non-small cell lung carcinoma.